Citigroup Maintains Neutral on Rain Oncology, Lowers Price Target to $1
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz has maintained a Neutral rating on Rain Oncology (NASDAQ:RAIN) and lowered the price target from $1.5 to $1.
September 18, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Citigroup has maintained a Neutral rating on Rain Oncology and lowered the price target from $1.5 to $1.
The lowering of the price target by Citigroup indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Rain Oncology's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100